Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Lenvatinib
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Letrozole
The First People's Hospital of Lianyungang
Polycystic Ovary Syndrome
1 trial -
MegestrolοΌYiningοΌ
The First People's Hospital of Lianyungang
Stage III Esophageal Squamous Cell Carcinoma
1 trial -
Metformin plus pioglitazone
The First People's Hospital of Lianyungang
Type 2 Diabetes
1 trial -
Methylprednisolone pulse
The First People's Hospital of Lianyungang
Glomerulonephritis, IGA
1 trial -
Methylprednisolone sodium succinate
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
1 trial -
Mimetic granules of Yiqi-Wenjing prescriptions
The First People's Hospital of Lianyungang
Chemotherapy-induced Peripheral Neuropathy
1 trial -
Mitoxantrone Hydrochloride Liposome
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (AML)
1 trial -
N-Acetylcysteine
The First People's Hospital of Lianyungang
Thrombotic Microangiopathies
1 trial -
N-Acetylcysteine (NAC) Treatment
The First People's Hospital of Lianyungang
Thrombotic Microangiopathy
1 trial -
Nedaplatin
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Nimotuzumab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Normal Saline
The First People's Hospital of Lianyungang
Postoperative Sleep Disturbance
1 trial -
Osimertinib
The First People's Hospital of Lianyungang
Non-small Cell Carcinoma
1 trial -
Oxaliplatin
The First People's Hospital of Lianyungang
Rectal Cancer
1 trial -
Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Paclitaxel
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Paclitaxel or docetaxel + Cisplatin or carboplatin
The First People's Hospital of Lianyungang
Uterine Cervical Neoplasms
1 trial -
Paclitaxel, Cisplatin Plus 5-FU (TCF)
The First People's Hospital of Lianyungang
Esophageal Cancer Stage IIB
1 trial -
Pembrolizumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR
The First People's Hospital of Lianyungang
Colorectal Neoplasms
1 trial -
Realgar-Indigo naturalis formula
The First People's Hospital of Lianyungang
Acute Promyelocytic Leukemia
1 trial -
Recombinant Human Albumin Injection
The First People's Hospital of Lianyungang
Hepatic Ascites
2 trials -
Recombinant Human Thrombopoietin (rhTPO)
The First People's Hospital of Lianyungang
Immune Thrombocytopenia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources